Physician profile
Mark David Kidwell
NPI 1366892150
$6,635.39
in general payments reported to CMS, 2019-2025
55 companies · $1,637 in 2025
The $1,637 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.37 · 2020: $449 · 2021: $1,239 · 2022: $1,200 · 2023: $1,001 · 2024: $1,055 · 2025: $1,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,693.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $848.89 | 2021-2025 | |
| Pfizer INC. | $769.20 | 2020-2025 | |
| Novo Nordisk INC | $618.89 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $580.24 | 2021-2025 | Rexulti |
| Amgen INC. | $412.77 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $292.73 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $241.99 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $236.09 | 2024-2025 | Auvelity, Symbravo |
| Gilead Sciences, INC. | $195.32 | 2019-2024 | Veklury, Ambisome |
| Merck Sharp & Dohme LLC | $163.89 | 2022-2025 | Gardasil 9, Capvaxive, Zerbaxa |
| Antares Pharma, INC. | $152.66 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Radius Health, INC. | $151.50 | 2021-2025 | Tymlos |
| Vanda Pharmaceuticals INC. | $126.94 | 2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.27 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $108.47 | 2020-2021 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kidwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.